<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="monograph-family" /><meta name="keywords" content="Erythropoietins; Epoetin; Anaemias: chronic renal failure; Darbepoetin; Methoxy polyethylene glycol-epoetin beta" /><meta name="IX" content="Erythropoietins; Epoetin; Anaemias: chronic renal failure; Darbepoetin; Methoxy polyethylene glycol-epoetin beta" /><title>Erythropoietins: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="4915.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="4915.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=4915.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="2076.htm">9 Nutrition and blood</a> &gt; <a href="4843.htm">9.1 Anaemias and some other blood disorders</a> &gt; <a href="4910.htm">9.1.3 Drugs used in hypoplastic, haemolytic, and renal anaemias</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="4910.htm" title="Previous: 9.1.3 Drugs used in hypoplastic, haemolytic, and renal anaemias">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="106107.htm" title="Next: DARBEPOETIN ALFA">Next page</a> ►</div></div></div></div><div id="p1"><div id="sideBar"><h2>See Also</h2><ul><li><h3>AHFS Drug Information (2)</h3></li><li><a href="http://www.medicinescomplete.com/mc/ahfs/2010/a301064.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Darbepoetin Alfa</a><div class="breadcrumb"><p><strong>AHFS Drug Information</strong> &gt; Blood Formation, Coagulation, and Thrombosis 20:00 &gt; Hematopoietic Agents 20:16</p></div></li><li><a href="http://www.medicinescomplete.com/mc/ahfs/2010/a392034.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Epoetin Alfa</a><div class="breadcrumb"><p><strong>AHFS Drug Information</strong> &gt; Blood Formation, Coagulation, and Thrombosis 20:00 &gt; Hematopoietic Agents 20:16</p></div></li></ul><ul><li><h3>Stockley's Interaction Alerts (5)</h3></li><li><a href="http://www.medicinescomplete.com/mc/alerts/2010/22839-k.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Darbepoetin</a><div class="breadcrumb"><p><strong>Stockley's Interaction Alerts</strong> &gt; Interactants: D &gt; Interactions of Darbepoetin</p></div></li><li><a href="http://www.medicinescomplete.com/mc/alerts/2010/12049-k.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Epoetin alfa</a><div class="breadcrumb"><p><strong>Stockley's Interaction Alerts</strong> &gt; Interactants: E &gt; Interactions of Epoetin alfa</p></div></li><li><a href="http://www.medicinescomplete.com/mc/alerts/2010/13785-e.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Epoetin beta</a><div class="breadcrumb"><p><strong>Stockley's Interaction Alerts</strong> &gt; Interactants: E &gt; Interactions of Epoetin beta</p></div></li><li><a class="seeAll" href="http://www.medicinescomplete.com/mc/related.htm?q=%22erythropoietins%22%22epoetin%22%22anaemias%22%22darbepoetin%22%22methoxy+polyethylene+glycol-epoetin+beta%22" onclick="pageTracker._trackEvent('Related-Topic','Related-See-All');">see all (5)</a></li></ul><ul><li><h3>British National Formulary (17)</h3></li><li><a href="4843.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">9.1 Anaemias and some other blood disorders</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 9 Nutrition and blood</p></div></li><li><a href="4844.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">9.1.1 Iron-deficiency anaemias</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 9 Nutrition and blood &gt; 9.1 Anaemias and some other blood disorders</p></div></li><li><a href="4901.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">9.1.2 Drugs used in megaloblastic anaemias</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 9 Nutrition and blood &gt; 9.1 Anaemias and some other blood disorders</p></div></li><li><a class="seeAll" href="http://www.medicinescomplete.com/mc/related.htm?q=%22erythropoietins%22%22epoetin%22%22anaemias%22%22darbepoetin%22%22methoxy+polyethylene+glycol-epoetin+beta%22" onclick="pageTracker._trackEvent('Related-Topic','Related-See-All');">see all (17)</a></li></ul><ul><li><h3>BNF for Children (14)</h3></li><li><a href="http://www.medicinescomplete.com/mc/bnfc/2011/4843.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">9.1 Anaemias and some other blood disorders</a><div class="breadcrumb"><p><strong>BNF for Children</strong> &gt; 9 Nutrition and blood</p></div></li><li><a href="http://www.medicinescomplete.com/mc/bnfc/2011/4844.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">9.1.1 Iron-deficiency anaemias</a><div class="breadcrumb"><p><strong>BNF for Children</strong> &gt; 9 Nutrition and blood &gt; 9.1 Anaemias and some other blood disorders</p></div></li><li><a href="http://www.medicinescomplete.com/mc/bnfc/2011/4901.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">9.1.2 Drugs used in megaloblastic anaemias</a><div class="breadcrumb"><p><strong>BNF for Children</strong> &gt; 9 Nutrition and blood &gt; 9.1 Anaemias and some other blood disorders</p></div></li><li><a class="seeAll" href="http://www.medicinescomplete.com/mc/related.htm?q=%22erythropoietins%22%22epoetin%22%22anaemias%22%22darbepoetin%22%22methoxy+polyethylene+glycol-epoetin+beta%22" onclick="pageTracker._trackEvent('Related-Topic','Related-See-All');">see all (14)</a></li></ul><ul><li><h3>Handbook on Injectable Drugs</h3></li><li><a href="http://www.medicinescomplete.com/mc/hid/2010/a597003.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Epoetin Alfa</a><div class="breadcrumb"><p><strong>Handbook on Injectable Drugs</strong> &gt; Monographs &gt; E</p></div></li></ul><ul><li><h3>Injectable Drugs Guide</h3></li><li><a href="http://www.medicinescomplete.com/mc/idg/2010/e10-mn0001.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Erythropoietins (epoetins, recombinant human erythropoietins)</a><div class="breadcrumb"><p><strong>Injectable Drugs Guide</strong> &gt; Injectable Drugs Guide &gt; Monographs &gt; E</p></div></li></ul><ul><li><h3>Martindale: The Complete Drug Reference (4)</h3></li><li><a href="http://www.medicinescomplete.com/mc/martindale/2009/1210-a8-z.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Anaemias</a><div class="breadcrumb"><p><strong>Martindale: The Complete Drug Reference</strong> &gt; Drugs and Ancillary Substances &gt; By therapeutic use &gt; Blood Products Plasma Expanders and Haemostatics</p></div></li><li><a href="http://www.medicinescomplete.com/mc/martindale/2009/20270-f.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Darbepoetin Alfa</a><div class="breadcrumb"><p><strong>Martindale: The Complete Drug Reference</strong> &gt; Drugs and Ancillary Substances &gt; By therapeutic use &gt; Blood Products Plasma Expanders and Haemostatics &gt; Drug Monographs</p></div></li><li><a href="http://www.medicinescomplete.com/mc/martindale/2009/ms-16635-r.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Epoetins</a><div class="breadcrumb"><p><strong>Martindale: The Complete Drug Reference</strong> &gt; Drugs and Ancillary Substances &gt; By therapeutic use &gt; Blood Products Plasma Expanders and Haemostatics &gt; Drug Monographs</p></div></li><li><a class="seeAll" href="http://www.medicinescomplete.com/mc/related.htm?q=%22erythropoietins%22%22epoetin%22%22anaemias%22%22darbepoetin%22%22methoxy+polyethylene+glycol-epoetin+beta%22" onclick="pageTracker._trackEvent('Related-Topic','Related-See-All');">see all (4)</a></li></ul><ul><li><h3>The Merck Index</h3></li><li><a href="http://www.medicinescomplete.com/mc/merck/2010/02824.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Darbepoetin Alfa</a><div class="breadcrumb"><p><strong>The Merck Index</strong> &gt; Monographs &gt; D &gt; DA</p></div></li></ul><ul><li><h3>Stockley's Drug Interactions (3)</h3></li><li><a href="http://www.medicinescomplete.com/mc/stockley/2010/int-E0E0E4E3E0R0D1696.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Darbepoetin alfa</a><div class="breadcrumb"><p><strong>Stockley's Drug Interactions</strong> &gt; Interactants, Alphabetically &gt; D</p></div></li><li><a href="http://www.medicinescomplete.com/mc/stockley/2010/int-E0E0E2E3E0R0D1696.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Epoetin alfa</a><div class="breadcrumb"><p><strong>Stockley's Drug Interactions</strong> &gt; Interactants, Alphabetically &gt; E</p></div></li><li><a href="http://www.medicinescomplete.com/mc/stockley/2010/int-E0E0E6E3E0R0D1696.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Epoetins</a><div class="breadcrumb"><p><strong>Stockley's Drug Interactions</strong> &gt; Interactants, Alphabetically &gt; E</p></div></li></ul><script type="text/javascript" src="scripts/sidebar.js"></script></div><div id="pB"><h1 id="_4915">Erythropoietins</h1><?highlighter on?><div id="pC" class="jN"><div><p><b>Epoetins</b> (recombinant
human erythropoietins) are used to treat symptomatic anaemia associated
with erythropoietin deficiency in chronic renal failure, to increase
the yield of autologous blood in normal individuals and to shorten
the period of symptomatic anaemia in patients receiving cytotoxic
chemotherapy. Epoetin beta is also used for the prevention of anaemia
in preterm neonates of low birth-weight; only unpreserved formulations
should be used in neonates because other preparations may contain
benzyl alcohol (see <a title="target-block: Excipients" href="29404.htm#_120000">Excipients</a>).</p><p><b>Darbepoetin</b> is a hyperglycosylated derivative of epoetin; it has a longer half-life
and can be administered less frequently than epoetin.</p><p><b>Methoxy polyethylene glycol-epoetin beta</b> is a continuous
erythropoietin receptor activator that is licensed for the treatment
of symptomatic anaemia associated with chronic kidney disease. It
has a longer duration of action than epoetin.</p><div id="_4915.1"><p>Other
factors, such as iron or folate deficiency, that contribute to the
anaemia of chronic renal failure should be corrected before treatment
and monitored during therapy. Supplemental iron may improve the response
in resistant patients. Aluminium toxicity, concurrent infection, or other inflammatory disease can impair the response to erythropoietin.</p></div><div id="_200198"><div class="cN"><h3 class="cBP">MHRA/CHM advice (December 2007) Erythropoietins—haemoglobin
concentration</h3><p>Overcorrection of haemoglobin concentration in
patients with chronic kidney disease may increase the risk of death
and serious cardiovascular events, and in patients with
cancer may increase the risk of thrombosis and related complications:</p><ul class="cBF"><li><p class="cQ">patients should not be treated with erythropoietins for
the licensed indications in chronic kidney disease or cancer in patients
receiving chemotherapy <i>unless</i> symptoms of anaemia
are present;</p></li><li><p class="cQ">the haemoglobin concentration should be maintained within
the range 10–12 g/100 mL;</p></li><li><p class="cQ">haemoglobin concentrations higher than 12 g/100 mL should
be avoided;</p></li><li><p class="cQ">the aim of treatment is to relieve symptoms of anaemia,
and in patients with chronic kidney disease to avoid the need for
blood transfusion; the haemoglobin concentration should not be increased
beyond that which provides adequate control of symptoms of anaemia
(in some patients, this may be achieved at concentrations lower than
the recommended range).</p></li></ul><p>See also MHRA/CHM advice below.</p></div></div><div id="_200200"><div class="cN"><h3 class="cBP">MHRA/CHM advice (December 2007 and July 2008) Erythropoietins—tumour
progression and survival in patients with cancer</h3><p>Clinical trial data show an unexplained excess mortality and
increased risk of tumour progression in patients with anaemia associated
with cancer who have been treated with erythropoietins. Many of these
trials used erythropoietins <i>outside</i> of the licensed
indications (i.e. overcorrected haemoglobin concentration or given
to patients who have <i>not</i> received chemotherapy):</p><ul class="cBF"><li><p class="cQ">erythropoietins licensed for the treatment of <i>symptomatic</i> anaemia associated with cancer, are licensed
only for patients who are receiving chemotherapy;</p></li><li><p class="cQ">the decision to use erythropoietins should be based on
an assessment of the benefits and risks for individual patients; blood
transfusion may be the preferred treatment for anaemia associated
with cancer chemotherapy, particularly in those with a good cancer
prognosis.</p></li></ul><p>See also MHRA/CHM advice above.</p></div></div><div id="_4915.2"><div class="cN"><h3 class="cBP">Pure red cell aplasia</h3><p>There have been very rare reports of pure red cell aplasia in
patients treated with erythropoietins. In
patients who develop a lack of efficacy with erythropoietin therapy
and with a diagnosis of pure red cell aplasia, treatment with erythropoietins
must be discontinued and testing for erythropoietin antibodies considered. Patients who develop pure red cell aplasia should <b>not</b> be switched to another form of erythropoietin.</p></div></div><div id="_200806"><div class="cN"><h2 class="cBR">NICE guidance</h2><h3 class="cBP">Epoetin alfa, beta and darbepoetin alfa for cancer
treatment-induced anaemia (May 2008)</h3><p>Erythropoietin analogues are <b>not</b> recommended
for routine use in the management of cancer treatment-induced anaemia,
but may be considered, in combination with intravenous iron, for:</p><ul class="cBF"><li><p class="cQ">women receiving platinum-based chemotherapy for ovarian
cancer who have symptomatic anaemia with a haemoglobin concentration
of 8 g/100 mL or lower (the use of erythropoietin analogues does not
preclude the use of existing approaches to the management of anaemia,
including blood transfusion when necessary);</p></li><li><p class="cQ">patients who cannot be given blood transfusions and who
have profound cancer treatment-related anaemia that is likely to have
an impact on survival.</p></li></ul><p>Patients currently treated with erythropoietin analogues for
the management of cancer treatment-related anaemia who do not fulfil
the criteria outlined above can continue therapy until they and their
specialists consider it appropriate to stop.</p></div></div></div></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_106107"><a href="106107.htm" title="DARBEPOETIN ALFA">DARBEPOETIN ALFA</a></li><li id="_4916"><a href="4916.htm" title="EPOETIN ALFA, BETA, THETA, and ZETA">EPOETIN ALFA, BETA, THETA, and ZETA</a></li><li id="_200087"><a href="200087.htm" title="METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA">METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="4910.htm">Previous: 9.1.3 Drugs used in hypoplastic, haemolytic, and renal anaemias</a> | <a class="top" href="4915.htm#">Top</a> | <a accesskey="]" href="106107.htm">Next: DARBEPOETIN ALFA</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>